Abstract: Systems, methods, and apparatuses are provided for dynamically matching an operator electronic control unit of a vehicle to a current functional state of vehicle functions of the vehicle. An electronic control unit is configured to ascertain a scope of functions of the vehicle, ascertain operating parameters of the vehicle that can influence an availability of at least one vehicle function that is part of the ascertained scope of functions of the vehicle, ascertain a current functional state of the operator electronic control unit from the ascertained scope of functions and the operating parameters, control the operator electronic control unit in such a way that the ascertained functional state can be output by the operator electronic control unit.

Abstract: The present invention pertains to a method for the identification of genetic variants that are associated with the severity of an infectious disease. The invention further pertains to a set of genetic factors associated with the severity of Human respiratory syncytial virus (HRSV) infection, for example in human infants. The genetic polymorphisms identified according to the present invention are for use in the diagnostic of infectious diseases and patient stratification in order to avoid or reduce the occurrence of fatal events during infection or to elect the most appropriate therapeutic approach to treat the disease.

Abstract: Disclosed is a method for estimating a condition of an object, in particular a cable or a pipeline, and/or material, in particular soil, surrounding the object. The method includes measuring a time course of values of the temperature of an optical fiber using a distributed temperature sensing system employing the optical fiber in proximity to the object, adjusting a value of at least one model parameter of plural model parameters of a thermal model, in particular relating to thermal properties of the object and the surrounding material, based on the measured temperature time course, comparing the adjusted value of at least one model parameter with a value determined theoretically and/or based on physical modeling and/or measured from another information source and/or predetermined and/or based on a value of a load and/or temperature the object is subjected to, to estimate the condition of the object and/or the surrounding material.

Abstract: A fiber measurement device for measuring a physical quantity by a fiber and a method for shaping a pulse of electromagnetic radiation are disclosed. The fiber measurement device comprises an electromagnetic radiation source and an adjustment unit. The electromagnetic radiation source generates at least one pulse of electromagnetic radiation as primary electromagnetic radiation to be coupled into the fiber, and an adjustment unit. The adjustment unit, prior to, during or after application of the primary electromagnetic radiation to the fiber, adjusts a shape of the at least one pulse for at least partially compensating a deviation between a target shape and an actual shape of the at least one pulse.

Abstract: A fiber measurement device for measuring a physical quantity by a fiber and a method for shaping a pulse of electromagnetic radiation are disclosed. The fiber measurement device comprises an electromagnetic radiation source and an adjustment unit. The electromagnetic radiation source generates at least one pulse of electromagnetic radiation as primary electromagnetic radiation to be coupled into the fiber, and an adjustment unit. The adjustment unit, prior to, during or after application of the primary electromagnetic radiation to the fiber, adjusts a shape of the at least one pulse for at least partially compensating a deviation between a target shape and an actual shape of the at least one pulse.

Abstract: The present invention relates to stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc comprising different buffer systems and stabilizers. In particular, it could be demonstrated that the physical stability of TNFR:Fc is significantly improved by using a citrate buffer system and lysine as stabilizer.

Abstract: The present invention provides a method for stable long-term storage of non-glycosylated recombinant human Granulocyte-Colony Stimulating Factor (G-CSF), wherein an aqueous acetate or glutamate buffered G-CSF composition containing the non-glycosylated recombinant human G-CSF and sorbital is cooled to a temperature of ?15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state and then increased in temperature to a temperature within the range of from 2° C. to 8° C. for a period of time adjusted to allow the composition to thaw and to obtain a liquid composition having a G-CSF content of at least 95% of the G-CSF content of the original composition.

Abstract: The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing the non-glycosylated recombinant human G-CSF and sorbital is cooled to a temperature of ?15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state and then increased in temperature to a temperature within the range of from 2° C. to 8° C. for a period of time adjusted to allow the composition to thaw and to obtain a liquid composition having a G-CSF content of at least 95% of the G-CSF content of the original composition.

Abstract: The present invention provides a method for stable long-term storage of non-glycosylated recombinant human Granulocyte-Colony Stimulating Factor (“G-CSF”), wherein an aqueous acetate or glutamate buffered G-CSF composition containing the non-glycosylated recombinant human G-CSF and sorbital is cooled to a temperature of ?15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state and then increased in temperature to a temperature within the range of from 2° C. to 8° C. for a period of time adjusted to allow the composition to thaw and to obtain a liquid composition having a G-CSF content of at least 95% of the G-CSF content of the original composition.

Abstract: The present invention relates to stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc comprising different buffer systems and stabilizers. In particular, it could be demonstrated that the physical stability of TNFR:Fc is significantly improved by using a citrate buffer system and lysine as stabilizer.

Abstract: The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing the non-glycosylated recombinant human G-CSF and sorbital is cooled to a temperature of ?15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state and then increased in temperature to a temperature within the range of from 2° C. to 8° C. for a period of time adjusted to allow the composition to thaw and to obtain a liquid composition having a G-CSF content of at least 95% of the G-CSF content of the original composition.

Abstract: The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing non-glycosylated recombinant human G-CSF and sorbitol is cooled to a temperature of ?15° C. or below to obtain a frozen G-CSF coFmposition, which frozen composition is then stored in the frozen state. The temperature of the frozen G-CSF composition is later increased to a temperature within the range of from 2° C. to 8° C. for a time selected to allow the G-CSF composition to thaw and to obtain a liquid G-CSF composition having a G-CSF content of at least 95% of the G-CSF content of the original composition.

Abstract: The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing non-glycosylated recombinant human G-CSF and sorbitol is cooled to a temperature of ?15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state. The temperature of the frozen G-CSF composition is later increased to a temperature within the range of from 2° C. to 8° C. for a time selected to allow the G-CSF composition to thaw and to obtain a liquid G-CSF composition having a G-CSF content of at least 95% of the G-CSF content of the original composition.